<!DOCTYPE html>
<html>
  <head>
    <title>RECOVER19 | Biased-Science Repository</title>
    <meta name="author" content="Claus Rinner">

	<link href="https://cdn.datatables.net/1.13.8/css/jquery.dataTables.min.css" rel="stylesheet">
	<script type="text/javascript" language="javascript" src="https://code.jquery.com/jquery-3.7.1.js"></script>
	<script src="https://cdn.datatables.net/1.13.8/js/jquery.dataTables.min.js"></script>
	
  </head>

  <body>

    <h1>Biased-Science Repository (Prototype)</h1>

<table id="bs-table" class="display" style="width:100%">
        <thead>
<tr><th>Group</th><th>Title</th><th>Author</th><th>Date</th><th>Source</th><th>Type</th><th>Method_or_issue</th><th>Key_conclusion</th><th>URL</th></tr>        </thead>
        <tbody>
<tr><td>1</td><td>Impact of population mixing between vaccinated and unvaccinated subpopulations on infectious disease dynamics: implications for SARS-CoV-2 transmission</td><td>David N. Fisman, Afia Amoako, and Ashleigh R. Tuite</td><td>April 25, 2022</td><td><a href='https://www.cmaj.ca/content/194/16/E573' target=_blank>Canadian Medical Association Journal</a></td><td>BS Article</td><td>Compartmental Model</td><td>Unvaccinated individuals have a higher risk of infection and contribute to infecting those who are vaccinated at a high rate.</td><td>https://www.cmaj.ca/content/194/16/E573</td></tr>
<tr><td>1</td><td>Error in key model input</td><td>Richard Schabas</td><td>44732</td><td>Canadian Medical Association Journal</td><td>Response</td><td>Model Parameters</td><td>The key input for the model has issues pertaining to a lack of data, accuracy, and reference.</td><td>https://www.cmaj.ca/content/194/24/E846</td></tr>
<tr><td>1</td><td>Study authors don’t consider waning SARS-CoV-2 immunity after vaccination in their model</td><td>James C. Doidge, Alex de Figueiredo, Trudo Lemmens, and Kevin Bardosh</td><td>44732</td><td>Canadian Medical Association Journal</td><td>Response</td><td>Model Parameters</td><td>The results are predetermined by the choice of model, parameters, and omission of waning immunity.</td><td>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9261953/</td></tr>
<tr><td>1</td><td>The authors respond to criticisms of their model parameters</td><td>David Fisman, Ashleigh Tuite, and Afia Amoako</td><td>44732</td><td>Canadian Medical Association Journal</td><td>BS Response</td><td>Source Credibility</td><td>Authors defend their original article by addressing some key concerns and responding with other studies.</td><td>https://www.cmaj.ca/content/194/24/E848</td></tr>
<tr><td>1</td><td>Fiction Disguised as Science to Promote Hatred</td><td>Byram W. Bridle</td><td>44677</td><td>Substack - COVID Chronicles</td><td>Debunk</td><td>Model Parameters</td><td>The conclusion of the paper may be reversed by changing the parameter for the baseline immunity among the unvaccinated.</td><td>https://viralimmunologist.substack.com/p/fiction-disguised-as-science-to-promote?s=r</td></tr>
<tr><td>1</td><td>OCLA Statement on CMAJ Fisman et al. Article Claiming Disproportionate Infection Risk from Unvaccinated Population, and on Negligent Media Reporting</td><td>Joseph Hickey and Denis G. Rancourt.</td><td>44678</td><td>Ontario Civil Liberties Association</td><td>Letter</td><td>Model Parameters</td><td>Correcting the parameter in the source paper shows no evidence of disproportionate infections caused the unvaccinated.</td><td>https://ocla.ca/ocla-statement-on-cmaj-fisman-et-al/</td></tr>
<tr><td>1</td><td>(Shortened Letter) Fisman et al.'s main conclusion does not follow from their model</td><td>Joseph Hickey and Denis G. Rancourt.</td><td>44680</td><td>Canadian Medical Association Journal</td><td>Letter</td><td>Model Parameters</td><td>Correcting the parameter in the source paper shows no evidence of disproportionate infections caused the unvaccinated.</td><td>https://www.cmaj.ca/content/fisman-et-als-main-conclusion-does-not-follow-their-model</td></tr>
<tr><td>1</td><td>Fisman et al.’s Psi (Ψ) index is ill-defined and leads to absurd interpretations</td><td>Joseph Hickey and Denis G. Rancourt.</td><td>45260</td><td>Correlation Research in the Public Interest</td><td>Debunk</td><td>Model Parameters</td><td>The construction of the Ψ index by the authors is proved to be incorrect and should not be referenced in future studies.</td><td>https://correlation-canada.org/fisman-et-al-psi-index-is-ill-defined-and-leads-to-absurd-interpretations/</td></tr>
<tr><td>1</td><td>Viral respiratory epidemic modelling of societal segregation based on vaccination status</td><td>Joseph Hickey and Denis G. Rancourt.</td><td>45274</td><td>Cureus</td><td>Response</td><td>Susceptible-Infectious-Recovered (SIR) Two-Population Model</td><td>Segregating between vaccinated and unvaccinated individuals does not produce any epidemiological advantage.</td><td>https://www.cureus.com/articles/203723-viral-respiratory-epidemic-modeling-of-societal-segregation-based-on-vaccination-status#!/metrics</td></tr>
<tr><td>1</td><td>Social segregation of unvaccinated people is not scientifically justified</td><td>Joseph Hickey and Denis G. Rancourt.</td><td>45274</td><td>Correlation Research in the Public Interest</td><td>Media Notice</td><td>Journal Bias</td><td>Unduly rejected from the journal that published the BS Article, a peer-reviewed paper which debunks the BS results has been recently published.</td><td>https://correlation-canada.org/media-notice-social-segregation-of-unvaccinated-not-scientifically-justified/</td></tr>
<tr><td>1</td><td>Guess What? Segregation of Unvaccinated People to Protect the 'Vaccinated' is NOT Supported by Modeling Practiced With Integrity</td><td>Byram W. Bridle</td><td>45274</td><td>Substack - COVID Chronicles</td><td>Response</td><td>Journal Bias</td><td>Disproven BS Article is still published, there is a massive request for retraction from the scientific community.</td><td>https://viralimmunologist.substack.com/p/guess-what-segregation-of-unvaccinated?utm_source=post-email-title&publication_id=592214&post_id=139796151&utm_campaign=email-post-title&isFreemail=true&r=1g2d4l&utm_medium=email</td></tr>
<tr><td>1</td><td>Meet Professor David Fisman of Canada</td><td>Steve Kirsch</td><td>44681</td><td>Substack - Steve Kirsch's Newsletter</td><td>Response</td><td>Model Parameters</td><td>Inaccurate selection of model parameters led to faulty results, although this is simple to disprove, these pro-narrative and false results are perpetuated widely across mainstream sources.</td><td>https://kirschsubstack.com/p/meet-professor-david-fisman-of-canada?utm_source=%2Fsearch%2Ffisman&utm_medium=reader2</td></tr>
<tr><td>1</td><td>Call for retraction of paper entitled: "Impact of population mixing between vaccinated and unvaccinated subpopulations on infectious disease dynamics: implications for SARS-CoV-2 transmission"</td><td>Jessica Rose</td><td>44679</td><td>Substack - Unacceptable Jessica</td><td>Debunk</td><td>Model Parameters</td><td>Conclusions of the paper are reversed with the change of a single parameter, and the choice of the parameter is not supported by actual data.</td><td>https://jessicar.substack.com/p/call-for-retraction-of-paper-entitled?s=r</td></tr>
<tr><td>1</td><td>Fisman's Fraud: The Rise of Canadian Hate Science</td><td>Regina Watteel</td><td>45237</td><td>RainSong Books</td><td>Book</td><td></td><td></td><td>https://www.amazon.ca/Fismans-Fraud-Rise-Canadian-Science/dp/1988363241</td></tr>
<tr><td>2</td><td>Risk of preterm birth, small for gestational age at birth, and stillbirth after covid-19 vaccination during pregnancy: population based retrospective cohort study</td><td>Deshayne B. Fell, Sheryll Dimanlig-Cruz, Annette K. Regan, Siri E. Håberg, Christopher A. Gravel, Laura Oakley, Gillian D. Alton, Eszter Török, Tavleen Dhinsa, Prakesh S. Shah, Kumanan Wilson, Ann E. Sprague, Darine El-Chaâr, Mark C. Walker, Jon Barrett, Nannette Okun, Sarah A. Buchan, Jeffrey C. Kwong, Sarah E. Wilson, Sandra I. Dunn, Shannon E. MacDonald, Shelley D. Dougan.</td><td>44790</td><td>The BMJ</td><td>BS Article</td><td>Population Based Retrospective Cohort Study</td><td>There is no association with vaccination during pregnancy and birth defects or stillbirths.</td><td>https://www.bmj.com/content/378/bmj-2022-071416/rr-0</td></tr>
<tr><td>2</td><td>Rapid response to: Risk of preterm birth, small for gestational age at birth, and stillbirth after covid-19 vaccination during pregnancy: population based retrospective cohort study</td><td>Angela Spelsberg and Ulrich Keil</td><td>44797</td><td>The BMJ</td><td>Response</td><td>Study Groups</td><td>The lack of relevant data and the differences between the unvaccinated and vaccinated groups may result in significant bias.</td><td>https://www.bmj.com/content/378/bmj-2022-071416/rr-0</td></tr>
<tr><td>3</td><td>Repetitive mRNA vaccination is required to improve the quality of broad-spectrum anti–SARS-CoV-2 antibodies in the absence of CXCL13</td><td>Marne Azarias Da Silva, Pierre Nioche, Calaiselvy Soudaramourty, Anne Bull-Maurer, Mounira Tiouajni, Dechuan Kong, Ouafa Zghidi-Abouzid, Morgane Picard, Ana Mendes-Frias, André Santa-Cruz, Alexandre Carvalho, Carlos Capela, Jorge Pedrosa, António Gil Castro, Paul Loubet, Albert Sotto, Laurent Muller, Jean-Yves Lefrant, Claire Roger, Pierre-Géraud Claret, Sandra Duvnjak, Tu-Anh Tran, Kenzo Tokunaga, Ricardo Silvestre, Pierre Corbeau, Fabrizio Mammano, Jérôme Estaquier.</td><td>45142</td><td>Sci Adv</td><td>BS Article</td><td>Clinical Trial</td><td>Obtaining three doses of the mRNA vaccine is required for protection against SARS-CoV-2 variants.</td><td>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10403221/</td></tr>
<tr><td>3</td><td>Let's See How COVID-19 'Vaccine' Papers Can Be Misleading</td><td>Byram W. Bridle</td><td>45195</td><td>Substack - COVID Chronicles</td><td>Response</td><td>Experimental Design</td><td>Due to the flawed experimental design, the results in the original paper are biased and do not show evidence that repeated vaccinated provides greater protection.</td><td>https://viralimmunologist.substack.com/p/lets-see-how-covid-19-vaccine-papers?utm_source=%2Fsearch%2Fdavid%2520fisman%2520byram%2520bridle&utm_medium=reader2</td></tr>
<tr><td>4</td><td>COVID Vaccine Hesitancy and Risk of a Traffic Crash</td><td>Donald A. Redelmeier, Jonathan Wang, and Deva Thiruchelvam</td><td>44897</td><td>The American Journal of Medicine</td><td>BS Article</td><td>Population-Based Longitudinal Cohort Analysis </td><td>There appears to be an association with increased risk of automobile accidents among unvaccinated individuals.</td><td>https://www.amjmed.com/article/S0002-9343(22)00822-1/fulltext</td></tr>
<tr><td>4</td><td>Addressing COVID Vaccine Hesitancy and Its Impact on Road Crashes</td><td>Victor Abiola Adepoju and Winifred Imoyera</td><td>45159</td><td>The American Journal of Medicine</td><td>Comment</td><td>Data Availability and Interpretation</td><td>Other factors that affect automobile accidents are not taken into account, and the classification of being vaccinated may significantly affect the validity of the study's results.</td><td>https://www.sciencedirect.com/science/article/abs/pii/S0002934323002620</td></tr>
<tr><td>4</td><td>Do unvaccinated people need to be counseled to drive slower?</td><td>Vinay Prasad</td><td>44909</td><td>Substack - Vinay Prasad's Observations and Thoughts</td><td>Response</td><td>Improper Comparison of Covariates</td><td>Since observational data cannot be solely relied upon, more randomized control trials (RCTs) are required to investigate the differences between the unvaccinated and vaccinated. </td><td>https://www.drvinayprasad.com/p/do-unvaccinated-people-need-to-be?utm_source=%2Fsearch%2FRedelmeier&utm_medium=reader2</td></tr>
<tr><td>4</td><td>Vaccine hesitancy was not shown to be associated with traffic safety or driver behavior</td><td>Jeff Wilson, Claus Rinner, Anna Pefoyo Kone, Edward Bosveld</td><td>45204</td><td>Frontiers in Public Health</td><td>Response</td><td>Data Availability and Interpretation</td><td>Re-analysis should be conducted by including additional control variables, and consideration must be placed on logical interpretation of the variables already included in the data set.</td><td>https://www.frontiersin.org/articles/10.3389/fpubh.2023.1204205/full</td></tr>
<tr><td>4</td><td>Comments on COVID Vaccine Hesitancy and Traffic Crash Risk</td><td>Richard Schabas, Jennifer Grant, Martha Fulford, and Neil Rau</td><td>45097</td><td>The American Journal of Medicine</td><td>Comment</td><td>Data Availability and Interpretation</td><td>Misinterpreting different sources, the authors made generalized and unsubstantiated claims about the unvaccinated.</td><td>https://doi.org/10.1016/j.amjmed.2023.02.021</td></tr>
<tr><td>5</td><td>N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting</td><td>Thomas E. Mulroney, Tuija Pöyry, Juan Carlos Yam-Puc, Maria Rust, Robert F. Harvey, Lajos Kalmar, Emily Horner, Lucy Booth, Alexander P. Ferreira, Mark Stoneley, Ritwick Sawarkar, Alexander J. Mentzer, Kathryn S. Lilley, C. Mark Smales, Tobias von der Haar, Lance Turtle, Susanna Dunachie, Paul Klenerman, James E. D. Thaventhiran, and Anne E. Willis </td><td>45266</td><td>Nature</td><td>BS Article</td><td>Animal Experiment and Clinical Trial</td><td>The authors identified and minimized any concerns pertaining to the formation of unintended proteins post inoculation with a Covid-19 mRNA vaccine.</td><td>https://www.nature.com/articles/s41586-023-06800-3</td></tr>
<tr><td>5</td><td>Ribosomal frameshifting and misreading of mRNA in COVID-19 vaccines produces “off-target” proteins and immune responses eliciting safety concerns: Comment on UK study by Mulroney et al.</td><td>David M Wiseman, L. Maria Gutschi, David J Speicher, Jessica Rose, and Kevin McKernan</td><td>45266</td><td>OSF Preprints</td><td>Response</td><td>Study Design and Omission of Key Points</td><td>Due to concerns with the study design, the authors cannot claim that there lacks evidence in the association between the formation of unintended proteins following vaccination and adverse outcomes.</td><td>https://osf.io/preprints/osf/nt8jh</td></tr>
<tr><td>5</td><td>(Shorter Version of Preprint) Ribosomal frameshifting and misreading of mRNA in COVID-19 vaccines produces “off-target” proteins and immune responses eliciting safety concerns: Comment on UK study by Mulroney et al.</td><td>David M Wiseman, L. Maria Gutschi, David J Speicher, Jessica Rose, and Kevin McKernan</td><td>45266</td><td>Nature</td><td>Comment</td><td>Study Design and Omission of Key Points</td><td>Due to concerns with the study design, the authors cannot claim that there lacks evidence in the association between the formation of unintended proteins following vaccination and adverse outcomes.</td><td>https://www.nature.com/articles/s41586-023-06800-3#article-comments</td></tr>
<tr><td>5</td><td>RE: N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting</td><td>Siguna Mueller</td><td>45271</td><td>Nature</td><td>Comment</td><td>Logical Contradiction with Conclusion</td><td>The assertion that there is no causal relationship between unintended protein formation and adverse outcomes following vaccination is due to criteria established, which does not allow for any form of individual or population level causation to be found.</td><td>https://www.nature.com/articles/s41586-023-06800-3#article-comments</td></tr>
<tr><td>6</td><td>COVID-19 lockdown revisionism</td><td>Blake Murdoch and Timothy Caulfield</td><td>45033</td><td>Canadian Medical Association Journal</td><td>BS Article</td><td>Analyzing Public Health Measures and Terminology</td><td>Use of certain terminology for public health policies may foster false impressions for these interventions and lower confidence in public institutions.</td><td>https://www.cmaj.ca/content/195/15/E552</td></tr>
<tr><td>6</td><td>Strawman argument or proto-factual revisionism?</td><td>Claus Rinner</td><td>45033</td><td>Canadian Medical Association Journal</td><td>Letter</td><td>Source of Evidence and Logical Fallacy</td><td>The authors presented obsolete articles and constructed arguments riddled with logical fallacies.</td><td>https://www.cmaj.ca/content/195/15/E552/tab-e-letters#re-strawman-argument-or-proto-factual-revisionism</td></tr>
<tr><td>6</td><td>RE: COVID-19 lockdown revisionism</td><td>Pooya Kazemi, Craig Bosenberg, Andrew Munro, Mark Roche, and Trevor Herrmann</td><td>45037</td><td>Canadian Medical Association Journal</td><td>Letter</td><td>Source of Evidence and Logical Fallacy</td><td>To support their argument, the authors selected low-quality survey and observational studies.</td><td>https://www.cmaj.ca/content/195/15/E552/tab-e-letters#re-covid-19-lockdown-revisionism</td></tr>
<tr><td>6</td><td>The unintended consequences of COVID-19 vaccine policy: why mandates, passports and restrictions may cause more harm than good</td><td>Kevin Bardosh, Alex de Figueiredo, Rachel Gur-Arie, Euzebiusz Jamrozik, James Doidge, Trudo Lemmens, Salmaan Keshavjee, Janice E Graham, and Stefan Baral</td><td>44707</td><td>BMJ Global Health </td><td>Debunk</td><td>Outline Comprehensive Set of Hypotheses</td><td>The current mandatory vaccination policies lack scientific validity and are counterproductive.</td><td>https://gh.bmj.com/content/7/5/e008684</td></tr>
<tr><td>7</td><td>COVID-19 Infection Rates in Vaccinated and Unvaccinated Inmates: A Retrospective Cohort Study</td><td>Luke Ko, Gary Malet, Lisa L. Chang, Huu Nguyen, Robert Mayes</td><td>45173</td><td>Cureus</td><td>BS Article</td><td>Incidence Rate </td><td>In high-density congregate settings, the study supports Covid-19 vaccination at a population level.</td><td>https://www.cureus.com/articles/179946-covid-19-infection-rates-in-vaccinated-and-unvaccinated-inmates-a-retrospective-cohort-study#!/</td></tr>
<tr><td>7</td><td>RE: COVID-19 Infection Rates in Vaccinated and Unvaccinated Inmates: A Retrospective Cohort Study</td><td>Claus Rinner</td><td>45197</td><td>Cureus</td><td>Comment</td><td>Misinterpretation of Findings</td><td>There is a mismatch between the findings from the study and the conclusions made by the authors, there is actually an increased risk of infection for boosted inmates. Also, despite there being no methodological foundation in the study, the BS authors claim that the bivalent vaccine is effective against severe outcomes. </td><td>https://www.cureus.com/articles/179946-covid-19-infection-rates-in-vaccinated-and-unvaccinated-inmates-a-retrospective-cohort-study#!/</td></tr>
<tr><td>8</td><td>Counterfactuals of effects of vaccination and public health measures on COVID-19 cases in Canada: What could have happened?</td><td>Nicholas H. Ogden, Patricia Turgeon, Aamir Fazil, Julia Clark, Vanessa Gabriele-Rivet, Theresa Tam, and Victoria Ng</td><td>July/August 2022</td><td>Can Commun Dis Rep</td><td>BS Article</td><td>Counterfactual Modelling</td><td>If not for restrictive public health measures, there could have been a greater number of infections, hospitalizations and deaths from Covid-19 in Canada.</td><td>https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2022-48/issue-7-8-july-august-2022/counterfactuals-effects-vaccination-public-health-measures-covid-19-cases-canada.html</td></tr>
<tr><td>8</td><td>RE: Counterfactuals of effects of vaccination and public health measures on COVID-19 cases in Canada: What could have happened?</td><td>David M. Vickers, John Hardie, Stefan Eberspaecher, Claudia Chaufan, and Steven Pelech </td><td>45055</td><td>Frontiers in Public Health    </td><td>Response</td><td>Lack of Sensitivity Analysis For Key Model Assumptions</td><td>The improper use of counterfactual analysis to study pandemic responses results in misguided justifications and conclusions.</td><td>https://www.frontiersin.org/articles/10.3389/fpubh.2023.1173673/full</td></tr>
<tr><td>9</td><td>Report 9: Impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand</td><td>Neil M. Ferguson, Daniel Laydon, Gemma Nedjati-Gilani, Natsuko Imai, Kylie Ainslie, Marc Baguelin, Sangeeta Bhatia, Adhiratha Boonyasiri, Zulma Cucunubá, Gina Cuomo-Dannenburg, Amy Dighe, Ilaria Dorigatti, Han Fu, Katy Gaythorpe, Will Green, Arran Hamlet, Wes Hinsley, Lucy C. Okell, Sabine van Elsland, Hayley Thompson, Robert Verity, Erik Volz, Haowei Wang, Yuanrong Wang, Patrick G.T. Walker, Caroline Walters, Peter Winskill, Charles Whittaker, Christl A. Donnelly, Steven Riley, and Azra C. Ghani.</td><td>43906</td><td>Imperial College COVID-19 Response Team</td><td>BS Report</td><td>Epidemiological Modelling</td><td>Until a vaccine was made available, the model predicted that in the absence of physical distancing for the entire population, millions would perish during the pandemic. </td><td>https://doi.org/10.25561/77482</td></tr>
<tr><td>9</td><td>The Flawed COVID-19 Model That Locked Down Canada</td><td>Peter S.T. and Onge Gaël Campan </td><td>43986</td><td>Montreal Economic Institute</td><td>Response</td><td>Coding Errors and Lack of Peer Review</td><td>Due to overprediction of deaths from a single model, many countries overreacted to the crisis by imposing stricter restrictions.</td><td>https://www.iedm.org/the-flawed-covid-19-model-that-locked-down-canada/</td></tr>
<tr><td>9</td><td>Commentary on Ferguson, et al., “Impact of Non-pharmaceutical Interventions (NPIs) to Reduce COVID-19 Mortality and Healthcare Demand”</td><td>S. Eubank, I. Eckstrand, B. Lewis, S. Venkatramanan, M. Marathe, and C. L. Barrett</td><td>44111</td><td>Bulletin of Mathematical Biology</td><td>Response</td><td>Outdated and Overly Simplified Modelling </td><td>The use of outdated and simplified modelling limits it applicability to examining counterfactual situations.</td><td>https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140590/</td></tr>
<tr><td>10</td><td>Impact of community masking on COVID-19: A cluster-randomized trial in Bangladesh</td><td>Jason Abaluck, Laura H. Kwong, Ashley Styczynski, Ashraful Haque, Md. Alamgir Kabir, Ellen Bates-Jefferys, Emily Crawford, Jade Benjamin-Chung, Shabib Raihan, Shadman Rahman, Salim Benhachmi, Neeti Zaman Bintee, Peter J. Winch, Maqsud Hossain, Hasan Mahmud Reza,  Abdullah All Jaber, Shawkee Gulshan Momen, Aura Rahman, Faika Laz Banti, Tahrima Saiha Huq, Stephen P. Luby, and Ahmed Mushfiq Mobarak</td><td>44532</td><td>Science</td><td>BS Article</td><td>Cluster-Randomized Trial </td><td>Encouraging community mask-wearing was shown to reduce the Covid-19 infections.</td><td>https://www.science.org/doi/10.1126/science.abi9069</td></tr>
<tr><td>10</td><td>The Bangladesh trial does not provide adaptable evidence for decision makers</td><td>Aleksi Raudasoja</td><td>44588</td><td>Science</td><td>Letter</td><td>Reducing Intervention Complexity </td><td>Resulting from the study design, there are significant limitations which prevents application of these findings for decision makers.</td><td>https://www.science.org/doi/10.1126/science.abi9069#elettersSection</td></tr>
<tr><td>10</td><td>Important study but results sensitive to modelling approaches</td><td>Chao Wang</td><td>44613</td><td>Science</td><td>Letter</td><td>Results Are Sensitive to Choice of Modelling Approach</td><td>Results vary according to choice of model, there is evidence of statistical errors, and there are flaws in the cost-benefit analysis.</td><td>https://www.science.org/doi/10.1126/science.abi9069#elettersSection</td></tr>
<tr><td>10</td><td>Major problems with the definition of "WHO-defined COVID symptoms"</td><td>Mitchell Lee</td><td>44647</td><td>Science</td><td>Letter</td><td>Inconsistent Definition Application and Survey Implementation</td><td>Definition of Covid-19 symptoms that the authors preregistered is vastly different than the definition used for analysis, and poor implementation of surveys introduces bias to the study.</td><td>https://www.science.org/doi/10.1126/science.abi9069#elettersSection</td></tr>
<tr><td>10</td><td>Reply to Mitchell Lee</td><td>Jason Abaluck</td><td>44676</td><td>Science</td><td>BS Response</td><td>Inconsistent Definition Application and Survey Implementation</td><td>Criticisms are addressed in detail with the claim that they are not serious and do not alter the results significantly.</td><td>https://www.science.org/doi/10.1126/science.abi9069#elettersSection</td></tr>
<tr><td>10</td><td>The Bangladesh Mask study: a Bayesian perspective</td><td>Norman Elliott Fenton</td><td>44683</td><td>ResearchGate</td><td>Debunk</td><td>Bayesian Causal Modelling</td><td>Use of a rigorous modelling approach shows that there is no effect of mask usage in reducing Covid-19 infection rates.</td><td>https://www.researchgate.net/publication/360320982_The_Bangladesh_Mask_study_a_Bayesian_perspective?channel=doi&linkId=62703fd83a23744a725db627&showFulltext=true</td></tr>
<tr><td>10</td><td>We've asked Science to retract the Bangladesh mask study</td><td>Steve Kirsch</td><td>44683</td><td>Substack - Steve Kirsch's Newsletter</td><td>Response</td><td>Incorrect Interpretation of Results</td><td>Misrepresentation of the causal effect of masking on Covid-19 infection rates should result in the article being retracted.</td><td>https://kirschsubstack.com/p/weve-asked-science-to-retract-the?s=w</td></tr>
<tr><td>10</td><td>Do Face Masks Reduce COVID-19 Spread in Bangladesh? Are the Abaluck et al. Results Reliable?</td><td>Denis G. Rancourt</td><td>44459</td><td>Denis Rancourt's Website</td><td>Debunk</td><td>Study Design</td><td>The results are invalidated by fundamental design flaws pertaining to unsuitable antibody detection methods and different handling of the control and treatment groups.</td><td>https://denisrancourt.ca/entries.php?id=106&name=2021_09_20_do_face_masks_reduce_covid_19_spread_in_bangladesh_are_the_abaluck_et_al_results_reliable</td></tr>
<tr><td>11</td><td>A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19</td><td>David R. Boulware, Matthew F. Pullen, Ananta S. Bangdiwala, Katelyn A. Pastick, Sarah M. Lofgren, Elizabeth C. Okafor, Caleb P. Skipper, Alanna A. Nascene, Melanie R. Nicol, Mahsa Abassi, Nicole W. Engen, Matthew P. Cheng, Derek LaBar, Sylvain A. Lother, Lauren J. MacKenzie, Glen Drobot, Nicole Marten, Ryan Zarychanski, Lauren E. Kelly, Ilan S. Schwartz, Emily G. McDonald, Radha Rajasingham, Todd C. Lee, and Kathy H. Hullsiek</td><td>43985</td><td>New England Journal of Medicine</td><td>BS Article</td><td>Randomized Double-Blind Placebo-Controlled Trial</td><td>No evidence that using hydroxychloroquine after high-risk or moderate-risk exposure prevents Covid-19 infection.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2016638</td></tr>
<tr><td>11</td><td>RE: A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19</td><td>Michael S. Avidan, Hakim-Moulay Dehbi, and Sinead Delany-Moretlwe</td><td>44027</td><td>New England Journal of Medicine</td><td>Letter</td><td>Misuse of Terminology and Additional Trials Are Required</td><td>Additional trials that examine preexposure and postexposure prophylaxis along with the inclusion of more participants should be conducted to accurately assess hydroxychloroquine use for Covid-19 infection.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2016638#article_letters</td></tr>
<tr><td>11</td><td>RE: A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19</td><td>Muhammad-Shahzeb Khan and Javed Butler</td><td>44027</td><td>New England Journal of Medicine</td><td>Letter</td><td>Incorrect Interpretation of Results</td><td>Since the trial is underpowered, the results are subject to inaccuracy, and there appears to be statistical evidence for possible benefit with no indicators of harm.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2016638#article_letters</td></tr>
<tr><td>11</td><td>RE: A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19</td><td>Babu L. Tekwani</td><td>44027</td><td>New England Journal of Medicine</td><td>Letter</td><td>Incorrect Interpretation of Results and Study Design</td><td>Determining whether an individual has contracted the virus should not be relied upon the analysis of symptoms alone, testing for the infection before and after hydroxychloroquine use should be done.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2016638#article_letters</td></tr>
<tr><td>11</td><td>Authors RE: A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19</td><td>Elizabeth C. Okafor, Katelyn A. Pastick, and Radha Rajasingham</td><td>44027</td><td>New England Journal of Medicine</td><td>BS Response</td><td>Responding to Criticisms</td><td>The authors defend their use of the term postexposure prophylaxis, stated that it was impractical to have obtained a larger trial sample, note that even if PCR testing was available at the time it would not have been a reliable testing mechanism, and still claim that widespread use of hydroxychloroquine is not necessary.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2016638#article_letters</td></tr>
<tr><td>11</td><td>Asking the wrong questions.</td><td>Gaurav Kumar</td><td>44048</td><td>New England Journal of Medicine</td><td>Comment</td><td>Study Question</td><td>It is recommended that focus should be instead placed on determining whether the intervention used during exposure could reduce the risk of serious symptoms for those who contract Covid-19.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2016638?page=3#article_comments</td></tr>
<tr><td>11</td><td>Unbelievably weak study methodology rife with result-canceling issues</td><td>John Graham</td><td>44048</td><td>New England Journal of Medicine</td><td>Comment</td><td>Selection Bias</td><td>Since use of hydroxychloroquine is exceptionally political, recruitment being done through social media increases the likelihood of selection bias.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2016638?page=2#article_comments</td></tr>
<tr><td>11</td><td>Zinc, Hydroxychloroquine and Azithromycin?</td><td>Alice Check</td><td>44048</td><td>New England Journal of Medicine</td><td>Comment</td><td>Conclusion Not Consistent With Other Studies</td><td>In contrast with findings from this trial, publication by Roland Derwand, Martin Scholz, and Vladimir Zelenko show that significantly fewer hospitalisations occurred when individuals exposed to Covid-19 used zinc plus low-dose hydroxychloroquine and azithromycin (https://doi.org/10.1016%2Fj.ijantimicag.2020.106214). </td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2016638?page=2#article_comments</td></tr>
<tr><td>11</td><td>Fundamentally flawed data</td><td>Jacqueline Fenaroli </td><td>44050</td><td>New England Journal of Medicine</td><td>Comment</td><td>Study Design</td><td>Determining whether an individual has contracted the virus should not be relied upon the analysis of symptoms alone, testing for the infection before and after hydroxychloroquine use should be done.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2016638?page=2#article_comments</td></tr>
<tr><td>11</td><td>Watanabe secondary analysis of boulware, HCQ effective p<0.01</td><td>Marc Imbert </td><td>44050</td><td>New England Journal of Medicine</td><td>Comment</td><td>Conclusion Not Consistent With Other Studies</td><td>Secondary analysis by Márcio Watanabe reveals that hydroxychloroquine is effective as an early treatment intervention.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2016638?page=2#article_comments</td></tr>
<tr><td>11</td><td>Hydroxychloroquine as post-exposure therapy is ineffective against COVID 19</td><td>Dr. Prem raj Pushpakaran </td><td>44051</td><td>New England Journal of Medicine</td><td>Comment</td><td>Conclusion is Not Definite</td><td>The study is not definitive in its conclusion, and hydroxychloroquine may still be used in combination with other treatments.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2016638?page=1#article_comments</td></tr>
<tr><td>11</td><td>What have we learned</td><td>Donald Rifas</td><td>44052</td><td>New England Journal of Medicine</td><td>Comment</td><td>Study Design</td><td>Determining whether an individual has contracted the virus should not be relied upon the analysis of symptoms alone, testing for prestudy antibody titer and for the infection before and after hydroxychloroquine use should be done.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2016638?page=1#article_comments</td></tr>
<tr><td>11</td><td>More concerned about low-income and homeless of postexposure prophylaxis</td><td>Chen Zhang </td><td>44053</td><td>New England Journal of Medicine</td><td>Comment</td><td>Study Design</td><td>Due to recruitment being done electronically, higher risk low-income individuals were excluded.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2016638?page=1#article_comments</td></tr>
<tr><td>11</td><td>Deep flaws in study</td><td>Michael Willman </td><td>44053</td><td>New England Journal of Medicine</td><td>Comment</td><td>Conclusion Not Consistent With Other Studies and Study Design</td><td>Study does not consider that hydroxychloroquine has been shown to be effective in reducing the number of deaths for those with major pre-existing health conditions.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2016638?page=1#article_comments</td></tr>
<tr><td>11</td><td>Hydroxychloroquine for the Prevention of Covid-19 — Searching for Evidence</td><td>Myron S. Cohen</td><td>43985</td><td>New England Journal of Medicine</td><td>Editorial</td><td>Study Design</td><td>There was no system in place to determine whether participants actually contracted the virus, adherence to the intervention could not be monitored, and the study did not recruit a representative sample.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMe2020388</td></tr>
<tr><td>11</td><td>Efficacy of Hydroxychloroquine as Prophylaxis for Covid-19</td><td>Márcio Watanabe</td><td>44033</td><td>arXivLabs</td><td>Debunk</td><td>Simple Regression Analysis</td><td>To correct for statistical oversights made by the authors, another simple statistical method shows that if used prior or right after exposure to Covid-19, hydroxychloroquine reduces the appearance of symptoms.</td><td>https://arxiv.org/abs/2007.09477</td></tr>
<tr><td>11</td><td>Randomized Controlled Trials of Early Ambulatory Hydroxychloroquine in the Prevention of COVID-19 Infection, Hospitalization, and Death: Meta-Analysis</td><td>Joseph A. Ladapo, John E. McKinnon, Peter A. McCullough, and Harvey A. Risch</td><td>44104</td><td>medRxiv</td><td>Debunk</td><td>Meta-Analysis of 5 Randomized Clinical Trials</td><td>Use of hydroxychloroquine reduces the severity of infection, hospitalization, and death.</td><td>https://www.medrxiv.org/content/10.1101/2020.09.30.20204693v1</td></tr>
<tr><td>12</td><td>RETRACTED: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis</td><td>Mandeep R Mehra, Sapan S Desai, Prof Frank Ruschitzka, and Amit N Patel</td><td>43973</td><td>The Lancet</td><td>BS Article</td><td>Multinational Registry Analysis</td><td>When used for treating Covid-19, prescribing hydroxychloroquine or chloroquine is associated with higher frequency of ventricular arrhythmias and decreased in-hospital survival.</td><td>https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31180-6/fulltext</td></tr>
<tr><td>12</td><td>Expression of concern: Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis</td><td>The Lancet Editors</td><td>43985</td><td>The Lancet</td><td>Comment</td><td>Data Validity</td><td>Due to serious scientific concerns raised, there was an expression of concern published by the editors which stated that there was an independent audit for the validity of the data commissioned.</td><td>https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31290-3/fulltext</td></tr>
<tr><td>12</td><td>Retraction—Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis</td><td>Mandeep R Mehra, Frank Ruschitzka, and Amit N Patel</td><td>43987</td><td>The Lancet</td><td>BS Comment</td><td>Data Validity</td><td>The authors retracted their paper since independent peer-review could not be conducted, this resulted from privacy concerns preventing the full dataset from being shared to the reviewers.</td><td>https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)31324-6/fulltext</td></tr>
<tr><td>12</td><td>An open letter to Mehra et al and The Lancet</td><td>James A. Watson, Rasimcan Meral, Richard Price, and Julie Simpson</td><td>43979</td><td>Zenodo</td><td>Letter</td><td>Methodology and Data Validity</td><td>Verifying the methodology and data for publications is critical since the results may mislead public perception and the progress of other studies.</td><td>https://zenodo.org/records/3871094</td></tr>
<tr><td>45273</td><td>Are medical journals dead?</td><td>Maryanne Demasi</td><td>45133</td><td>Substack - Maryanne Demasi, reports</td><td>Response</td><td>Data Validity</td><td>Resulting from discrepancies found in the data, the Lancet and New England Journal of Medicine retracted studies claiming that hydroxychloroquine increased the mortality of hospitalised covid patients.</td><td>https://blog.maryannedemasi.com/p/are-medical-journals-dead?utm_source=substack&utm_medium=email</td></tr>
<tr><td>45273</td><td>WHO Halts Hydroxychloroquine Testing Over Safety Concerns</td><td>Catherine Offord</td><td>43978</td><td>The Scientist</td><td>News/Opinion</td><td>Data Validity</td><td>Prior to the announcement of retraction for two articles, the World Health Organization suspended testing of hydroxychloroquine in response to the articles.</td><td>https://www.the-scientist.com/news-opinion/who-halts-hydroxychloroquine-testing-after-safety-warning-67573</td></tr>
<tr><td>45273</td><td>Lancet, NEJM Retract Surgisphere Studies on COVID-19 Patients</td><td>Catherine Offord</td><td>43986</td><td>The Scientist</td><td>News/Opinion</td><td>Data Validity</td><td>A study that suspended testing of hydroxychloroquine in response to the two retracted articles has been reinstated.</td><td>https://www.the-scientist.com/news-opinion/lancet-retracts-surgispheres-study-on-hydroxychloroquine-67613</td></tr>
<tr><td>45273</td><td>Two elite medical journals retract coronavirus papers over data integrity questions</td><td>Charles Piller and Kelly Servick</td><td>43986</td><td>Science</td><td>News/Opinion</td><td>Data Validity</td><td>In addition to the two retracted articles, there was a preprint on ivermectin that used the same invalidated data source which disappeared shortly after the retractions, but was reported through some news sources.</td><td>https://www.science.org/content/article/two-elite-medical-journals-retract-coronavirus-papers-over-data-integrity-questions</td></tr>
<tr><td>45273</td><td>Lancetgate: why was this “monumental fraud” not a huge scandal?</td><td>Daniel Espinosa</td><td>44063</td><td>Dissident Voice</td><td>Response</td><td>Data Validity</td><td>Prior to its retraction, the conclusions of the BS Article resulted in the suspension for studies on hydroxychloroquine, and social media censorship for physicians sharing their success with using it on their patients.</td><td>https://dissidentvoice.org/2020/08/lancetgate-why-was-this-monumental-fraud-not-a-huge-scandal/</td></tr>
<tr><td>45273</td><td>The Lancet Alters Editorial Practices After Surgisphere Scandal</td><td>Catherine Offord</td><td>44096</td><td>The Scientist</td><td>News/Opinion</td><td>Data Validity</td><td>After retracting a study with data issues, the Lancet revised their publication procedure by including additional peer-review requirements and declarations that must be signed by each author.</td><td>https://www.the-scientist.com/news-opinion/the-lancet-alters-editorial-practices-after-surgisphere-scandal-67953</td></tr>
<tr><td>13</td><td>Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med</td><td>Mandeep R. Mehra, Sapan S. Desai, SreyRam Kuy, Timothy D. Henry, and Amit N. Patel</td><td>43952</td><td>New England Journal of Medicine</td><td>BS Article</td><td>Multivariable Logistic Regression</td><td>There is a higher risk of in-hospital death for patients with underlying cardiovascular disease that are hospitalized with Covid-19.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2007621?query=recirc_curatedRelated_article</td></tr>
<tr><td>13</td><td>Retraction: Cardiovascular Disease, Drug Therapy, and Mortality in Covid-19. N Engl J Med. DOI: 10.1056/NEJMoa2007621.</td><td>Mandeep R. Mehra, Sapan S. Desai, SreyRam Kuy, Timothy D. Henry, and Amit N. Patel</td><td>43986</td><td>New England Journal of Medicine</td><td>BS Letter</td><td>Data Validity</td><td>Since the primary data source could not be verified, the BS authors request retracting the article.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMc2021225</td></tr>
<tr><td>14</td><td>Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data</td><td>Eric J Haas, Frederick J Angulo, John M McLaughlin, Emilia Anis, Shepherd R Singer, Farid Khan, Nati Brooks, Meir Smaja, Gabriel Mircus, Kaijie Pan, Jo Southern, David L Swerdlow, Luis Jodar, Yeheskel Levy, and Sharon Alroy-Preis</td><td>44321</td><td>The Lancet</td><td>BS Article</td><td>Negative Binomial Regression Model</td><td>Focusing on the population of Israel, two doses of Pfizer’s Covid-19 vaccine are 95% effective across all age groups.</td><td>https://www.thelancet.com/article/S0140-6736(21)00947-8/fulltext</td></tr>
<tr><td>14</td><td>Study Claims Pfizer Vaccine is 95% Effective in Over 65s. But Should That Be 74%?</td><td>Will Jones</td><td>44323</td><td>The Daily Sceptic</td><td>Response</td><td>Data Analysis</td><td>Since the declining infection rate is not taken into account, vaccine effectiveness is overestimated.</td><td>https://dailysceptic.org/2021/05/07/study-claims-pfizer-vaccine-is-95-effective-in-over-65s-but-should-that-be-74/</td></tr>
<tr><td>14</td><td>Is the Pfizer vaccine as effective as claimed?</td><td>Norman Fenton and Martin Neil</td><td>44333</td><td>Substack - Where are the numbers? by Norman Fenton and Martin Neil</td><td>Response</td><td>Data Analysis</td><td>Vaccine effectiveness is overestimated since the decreasing infection rate is not adjusted for, and there is different testing protocols for vaccinated and unvaccinated individuals.</td><td>https://wherearethenumbers.substack.com/p/important-caveats-to-pfizer-vaccine?</td></tr>
<tr><td>14</td><td>The curious case of Dr Sharon Alroy-Preis and the claims of safety and effectiveness of the Pfizer vaccine</td><td>Norman Fenton and Martin Neil</td><td>44936</td><td>Substack - Where are the numbers? by Norman Fenton and Martin Neil</td><td>Response</td><td>Conflicts of Interest</td><td>8 out of 15 of the listed authors do not declare any conflict of interest while holding stock/stock options in Pfizer.</td><td>https://wherearethenumbers.substack.com/p/alroy-preis</td></tr>
<tr><td>14</td><td>The Lancet has become a laughing stock</td><td>Norman Fenton and Martin Neil</td><td>44940</td><td>Substack - Where are the numbers? by Norman Fenton and Martin Neil</td><td>Response</td><td>Data Analysis and Conflicts of Interest</td><td>For 20 months, the journal did not publish the original rapid response since the BS authors did not respond. The editors offered an opportunity to submit a updated response, which was ultimately rejected. The revised response noted that the study did not include all reported cases in their computations, and there are numerous BS authors that have conflicts of interests not explicitly stated.</td><td>https://wherearethenumbers.substack.com/p/the-lancet-has-become-a-laughing</td></tr>
<tr><td>14</td><td>Proof: The Lancet is a very corrupt journal</td><td>Steve Kirsch</td><td>44940</td><td>Substack - Steve Kirsch's Newsletter</td><td>Response</td><td>Journal Bias</td><td>After being informed of flaws in a publication by a letter, the journal rejects the letter and does not correct or retract the article.</td><td>https://kirschsubstack.com/p/proof-the-lancet-is-a-very-corrupt?utm_source=twitter&utm_campaign=auto_share&r=o7iqo</td></tr>
<tr><td>14</td><td>The Lancet and the Pfizer Vaccine: A Case Study in Academic Censorship and Deceit in the Covid Era</td><td>Norman Fenton and Martin Neil</td><td>44943</td><td>Research Gate</td><td>Response</td><td>Data Analysis, Journal Bias and Conflicts of Interest</td><td>A report provides a comprehensive summary for the rejection of two responses to the BS article.</td><td>https://www.researchgate.net/publication/367207215_The_Lancet_and_the_Pfizer_Vaccine_A_Case_Study_in_Academic_Censorship_and_Deceit_in_the_Covid_Era?channel=doi&linkId=63c6ed70d9fb5967c2e44b65&showFulltext=true</td></tr>
<tr><td>14</td><td>The Lancet heavily redact their response to our subject access request for internal correspondence relating to rejection of our letter about Pfizer study</td><td>Norman Fenton and Martin Neil</td><td>44999</td><td>Substack - Where are the numbers? by Norman Fenton and Martin Neil</td><td>Response</td><td>Journal Bias</td><td>Regarding the rejection of both the original and revised letter, a subject access information request was submitted to Elsevier, the publisher of The Lancet. Ultimately, the records received were largely redacted.</td><td>https://wherearethenumbers.substack.com/p/the-lancet-heavily-redact-their-response</td></tr>
<tr><td>15</td><td>BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting</td><td>Noa Dagan, Noam Barda, Eldad Kepten, Oren Miron, Shay Perchik, Mark A. Katz, Miguel A. Hernán, Marc Lipsitch, Ben Reis, and Ran D. Balicer</td><td>44251</td><td>New England Journal of Medicine</td><td>BS Article</td><td>Kaplan-Meier Estimator</td><td>Consistent with findings from randomized trials, the Covid-19 mRNA vaccine is effective for a variety of health outcomes from the virus.</td><td>https://www.nejm.org/doi/full/10.1056/nejmoa2101765</td></tr>
<tr><td>15</td><td>Covid-19: Pfizer BioNTech vaccine reduced cases by 94% in Israel, shows peer reviewed study</td><td>Jacqui Wise</td><td>44252</td><td>The BMJ</td><td>BS News/Opinion</td><td>Authority Bias</td><td>Summarizing the findings from the BS Article, this article states that publication is rigorous and thorough.</td><td>https://www.bmj.com/content/372/bmj.n567</td></tr>
<tr><td>15</td><td>Rapid Response: Who really needs a Covid-19 vaccine?</td><td>Allan S. Cunningham</td><td>44255</td><td>The BMJ</td><td>Response</td><td>Level of Analysis</td><td>Since the study focuses on population benefit as opposed to individual benefit, it does not capture the fact that there is little to no individual benefit of vaccination, yet there is risk of individual adverse vaccine effects.</td><td>https://www.bmj.com/content/372/bmj.n567/rr</td></tr>
<tr><td>15</td><td>RE: BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting</td><td>Stefan Roest, Rogier A.S. Hoek, and Olivier C. Manintveld</td><td>44307</td><td>New England Journal of Medicine</td><td>Letter</td><td>Lacking Subgroup Analysis</td><td>Additional analysis is requested for vaccine effectiveness in recipients for organ transplants.</td><td>https://www.nejm.org/doi/full/10.1056/nejmoa2101765#article_letters</td></tr>
<tr><td>15</td><td>The authors reply: Roest et al.</td><td>Noam Barda, Noa Dagan, and Ran D. Balicer</td><td>44307</td><td>New England Journal of Medicine</td><td>BS Response</td><td>Subgroup Analysis</td><td>Constituting of a small minority of organ recipients, vaccine effectiveness is found to be high for the immunodeficiency subgroup.</td><td>https://www.nejm.org/doi/full/10.1056/nejmoa2101765#article_letters</td></tr>
<tr><td>15</td><td>[The Censorship of Covid Science: Three Examples] First letter (The New England Journal of Medicine, March 2021)</td><td>Eyal Shahar</td><td>44256</td><td>Brownstone Institute</td><td>Rejected Letter</td><td>Additional Endpoints</td><td>The Brownstone Institute published a rejected letter which requests further analysis for two additional endpoints: all-cause death and any hospitalization.</td><td>https://brownstone.org/articles/the-censorship-of-covid-science-three-examples/</td></tr>
<tr><td>15</td><td>Rapid Response: Concerns regarding the estimated efficiency of Pfizer’s Covid-19 vaccine in two large-scale observational studies in Israel</td><td>Retsef Levi</td><td>44346</td><td>The BMJ</td><td>Response</td><td>Upward Bias</td><td>There may be significant upward bias due to the lack of controls and differing testing protocols for vaccinated and unvaccinated individuals.</td><td>https://www.bmj.com/content/372/bmj.n567/rr-0</td></tr>
<tr><td>15</td><td>[The Censorship of Covid Science: Three Examples] Third letter (The British Medical Journal, June 2022)</td><td>Eyal Shahar</td><td>44713</td><td>Brownstone Institute</td><td>Rejected Response</td><td>Endpoint Misclassification</td><td>The Brownstone Institute published a rejected rapid response for the Israel studies which claim vaccine effectiveness against death from Covid-19 suffer from 50% misclassification of the mortality endpoint.</td><td>https://brownstone.org/articles/the-censorship-of-covid-science-three-examples/</td></tr>
<tr><td>15</td><td>Rapid Response: A cohort study of the COVID-19 vaccine should clarify the effects of the "premature efficacy bias"</td><td>Keiji Hayashi</td><td>44391</td><td>The BMJ</td><td>Response</td><td>Premature Efficacy Bias </td><td>The results from the study may be subject to premature efficacy bias where individuals that are PCR positive, recently exposed to the virus, or are symptomatic may defer vaccination.</td><td>https://www.bmj.com/content/372/bmj.n567/rr-1</td></tr>
<tr><td>15</td><td>Use of a null assumption to re-analyze data collected through a rolling cohort subject to selection bias due to informative censoring</td><td>Mark Reeder</td><td>44432</td><td>Zenodo</td><td>Response</td><td>Selection Bias and Data Transparency</td><td>Since those with Covid-19 symptoms experienced delays in receiving the vaccine, the resulting selection bias from the BS Article is estimated using a novel method. Also, there are issues with data transparency due to the total number of hospitalizations and deaths from Covid-19 during the study period being withheld.</td><td>https://zenodo.org/records/5243901#.Y8L23BXP0uU</td></tr>
<tr><td>15</td><td>Sources of bias in observational studies of covid-19 vaccine effectiveness</td><td>Kaiser Fung, Mark Jones, and Peter Doshi</td><td>45011</td><td>The Journal of Evaluation in Clinical Practice</td><td>Response</td><td>Age Bias and Background Infection Rate Bias</td><td>Three major sources of bias are discussed for observational studies that estimate vaccine effectiveness.</td><td>https://onlinelibrary.wiley.com/doi/10.1111/jep.13839</td></tr>
<tr><td>15/16</td><td>Pfizer vaccine and COVID mortality: a call for retraction of publications from Israel</td><td>Eyal Shahar</td><td>44735</td><td>Medium</td><td>Debunk</td><td>Endpoint Misclassification</td><td>Both papers should be retracted due to the Israel studies suffering from 50% misclassification of the mortality endpoint.</td><td>https://shahar-26393.medium.com/pfizer-vaccine-and-covid-mortality-a-call-for-retraction-of-publications-from-israel-15f5e67e6f7f</td></tr>
<tr><td>16</td><td>Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study</td><td>Noam Barda, Noa Dagan, Cyrille Cohen, Miguel A Hernán, Marc Lipsitch, Isaac S Kohane, Ben Y Reis, and Ran D Balicer</td><td>44498</td><td>The Lancet</td><td>BS Article</td><td>Kaplan-Meier Estimator</td><td>Compared to the second dose, receiving the third dose of a Covid-19 mRNA vaccine is effective in mitigating severe Covid-related outcomes.</td><td>https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)02249-2/fulltext</td></tr>
<tr><td>16</td><td>[The Censorship of Covid Science: Three Examples] Second letter (The Lancet, October 2021)</td><td>Eyal Shahar</td><td>44470</td><td>Brownstone Institute</td><td>Rejected Letter</td><td>Methodology</td><td>The Brownstone Institute published a rejected letter which requests further analysis for excluded events that occurred during the first six days of follow up.</td><td>https://brownstone.org/articles/the-censorship-of-covid-science-three-examples/</td></tr>
<tr><td>16</td><td>COVID vaccine research in Israel: no troubling questions please</td><td>Eyal Shahar</td><td>44727</td><td>Medium</td><td>Response</td><td>Upward Bias</td><td>The mortality data from the Israel Central Bureau of Statistics indicates that there was at least one period of extensive over-counting of Covid-19 deaths, this indicates that there is an upward bias of vaccine effectiveness.</td><td>https://shahar-26393.medium.com/covid-vaccine-research-in-israel-no-troubling-questions-please-ee7f8389af1b</td></tr>
<tr><td>17</td><td>Nirmatrelvir Use and Severe Covid-19 Outcomes during the Omicron Surge</td><td>Ronen Arbel, Yael Wolff Sagy, Moshe Hoshen, Erez Battat, Gil Lavie, Ruslan Sergienko, Michael Friger, Jacob G. Waxman, Noa Dagan, Ran Balicer, Yatir Ben-Shlomo, Alon Peretz, Shlomit Yaron, Danielle Serby, Ariel Hammerman, and Doron Netzer</td><td>44805</td><td>New England Journal of Medicine</td><td>BS Article</td><td>Cox Proportional-Hazards Regression Model</td><td></td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2204919</td></tr>
<tr><td>17</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr>
<tr><td>17</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></tr>
<tr><td>18</td><td>Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study</td><td>Lisa Lundberg-Morris, Susannah Leach, Yiyi Xu, Jari Martikainen, Ailiana Santosa, Magnus Gisslén, Huiqi Li, Fredrik Nyberg, and Maria Bygdell</td><td>45252</td><td>The BMJ</td><td>BS Article</td><td>Cox Proportional-Hazards Regression Model</td><td>Receiving a Covid-19 vaccination prior to infection reduces the risk of being diagnosed with a post-Covid-19 condition.</td><td>https://www.bmj.com/content/383/bmj-2023-076990</td></tr>
<tr><td>18</td><td>Rapid Response: Concern about Covid-19 vaccine efficiency related to biased analyses not captured by the review process Re: Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study</td><td>Xavier Azalbert, Alexis Lacout, Jean-François Lesgards, Christian Perronne, Corinne Reverbel, Jean Marc Sabatier, and Martin Zizi</td><td>45258</td><td>The BMJ</td><td>Response</td><td>Cohort Bias and Additional Analysis Required</td><td>Analysis of vaccine effectiveness should be done by variant to mitigate cohort bias, and it was not discussed that the higher number of vaccine doses is associated with greater risk of infection.</td><td>https://www.bmj.com/content/383/bmj-2023-076990/rr-0</td></tr>
<tr><td>18</td><td>Rapid Response: Re: Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study</td><td>Noel S Weiss</td><td>45262</td><td>The BMJ</td><td>Response</td><td>Estimation Accuracy</td><td>In addition to the number of vaccinations determining the post-Covid-19 condition incidence, there is a relationship between vaccination reducing the risk of infection which lowers the possibility of experiencing a post-Covid-19 condition.</td><td>https://www.bmj.com/content/383/bmj-2023-076990/rr-1</td></tr>
<tr><td>18</td><td>Rapid Response: Why the Lundberg-Morris et al. study shows puzzling, diverging results</td><td>Jarle Aarstad</td><td>45263</td><td>The BMJ</td><td>Response</td><td>Extrapolation Bias</td><td>Extrapolation bias may be present due to the lack of consideration for groups that have few overlapping data points along various dimensions.</td><td>https://www.bmj.com/content/383/bmj-2023-076990/rr-4</td></tr>
<tr><td>18</td><td>Rapid Response: Re: Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study - Reply by the authors to Lacout et al rapide response</td><td>Fredrik Nyberg and Maria Bygdell</td><td>45265</td><td>The BMJ</td><td>BS Response</td><td>Responding to Criticisms</td><td>The BS authors defend their results by stating that other recommended analyses and comparisons are not relevant or misleading.</td><td>https://www.bmj.com/content/383/bmj-2023-076990/rr-2</td></tr>
<tr><td>18</td><td>Rapid Response: Nyberg and Bygdell explaining away why vaccinated have the highest mortality rate contradicts what the data indicate in adjusted models</td><td>Jarle Aarstad</td><td>45265</td><td>The BMJ</td><td>Response</td><td>Conclusion Not Consistent With Results</td><td>Since it is shown that the vaccinated experienced a greater probability of post-Covid-19 conditions in the partially and fully adjusted models, it is also likely that vaccinated individuals would have a greater probability of mortality.</td><td>https://www.bmj.com/content/383/bmj-2023-076990/rr-5</td></tr>
<tr><td>18</td><td>Rapid Response: The refinement of comorbidities is very important for the study of post-covid-19 condition</td><td>Shuanggang Chen</td><td>45273</td><td>The BMJ</td><td>Response</td><td>Additional Analysis Required</td><td>Further analysis taking into consideration the influence that comorbidities and psychiatric disease have in diagnosing post-Covid-19 conditions is required.</td><td>https://www.bmj.com/content/383/bmj-2023-076990/rr-6</td></tr>
<tr><td>18</td><td>Conclusions about vaccine effectiveness against post-Covid 19 condition are not supported by the data</td><td>Oliver Hirsch and Boris Kotchoubey</td><td>45302</td><td>The BMJ</td><td>Response</td><td></td><td></td><td>https://www.bmj.com/content/383/bmj-2023-076990/rr-7</td></tr>
<tr><td>19</td><td>BNT162b2 Vaccine Booster and Mortality Due to Covid-19</td><td>Ronen Arbel, Ariel Hammerman, Ruslan Sergienko, Michael Friger, Alon Peretz, Doron Netzer, and Shlomit Yaron</td><td>44538</td><td>New England Journal of Medicine</td><td>BS Article</td><td>Cox Proportional-Hazards Regression Model</td><td>Compared to individuals which did not receive a Covid-19 booster, those that received the booster at least 5 months after a second dose experienced a 90% reduction in Covid-19 related mortality. </td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2115624</td></tr>
<tr><td>19</td><td>Booster Doses and Prioritizing Lives Saved</td><td>Minal K. Patel</td><td>44538</td><td>New England Journal of Medicine</td><td>BS Editorial</td><td>Summarizing Results</td><td>The methodology employed is reasonable despite there not being a formal estimation of booster effectiveness.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMe2117592?query=recirc_curatedRelated_article</td></tr>
<tr><td>19</td><td>RE: BNT162b2 Vaccine Booster and Covid-19 Mortality</td><td>Thomas Rohban</td><td>44601</td><td>New England Journal of Medicine</td><td>Letter</td><td>Omitted Outcomes and Variables</td><td>Robust estimates of the booster effect may be achieved by including the outcome of all-cause mortality instead of Covid-19 mortality, and it is recommended to include the number of boosted individuals required to prevent a single Covid-19 related death.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2115624#article_letters</td></tr>
<tr><td>19</td><td>RE: BNT162b2 Vaccine Booster and Covid-19 Mortality</td><td>Stefan Pilz</td><td>44601</td><td>New England Journal of Medicine</td><td>Letter</td><td>Lacking Comparisons</td><td>Comparing risk estimates for boosted and unvaccinated or recovered individuals would assist with interpretation of the results.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2115624#article_letters</td></tr>
<tr><td>19</td><td>Authors RE: BNT162b2 Vaccine Booster and Covid-19 Mortality</td><td>Ronen Arbel, Ruslan Sergienko, and Ariel Hammerman</td><td>44601</td><td>New England Journal of Medicine</td><td>BS Response</td><td>Responding to Criticisms</td><td>Performing the analysis requested, compared to unvaccinated individuals, there is a lower risk of non-Covid-19 mortality outcomes for individuals that received two doses. In addition, they postulate that administering the booster is a cost effective intervention.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2115624#article_letters</td></tr>
<tr><td>19</td><td>Potential “Healthy Vaccinee Bias” in a Study of BNT162b2 Vaccine against Covid-19</td><td>Tracy B. Høeg, Ram Duriseti, and Vinay Prasad</td><td>45127</td><td>New England Journal of Medicine</td><td>Letter</td><td>Healthy Vaccinee Bias</td><td>There may be an overestimation of booster effectiveness since the unadjusted differences in mortality related and not related to Covid-19 were similar.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMc2306683?query=featured_secondary</td></tr>
<tr><td>19</td><td>Authors RE: Potential “Healthy Vaccinee Bias” in a Study of BNT162b2 Vaccine against Covid-19</td><td>Ronen Arbel, Ruslan Sergienko, Doron Netzer, Ariel Hammerman, Michael Friger, Alon Peretz, Talish Razi, Hadar Duskin-Bitan, and Shlomit Yaron</td><td>45127</td><td>New England Journal of Medicine</td><td>BS Response</td><td>Responding to Criticisms</td><td>Regarding the healthy vaccinee bias, all individuals began with an unboosted status, which changed to boosted 7 days after vaccination, and a majority of participants provided follow-up data for both the boosted and nonboosted groups.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMc2306683?query=featured_secondary</td></tr>
<tr><td>19</td><td>When will Booster #2 be available in the US?</td><td>Sharon Smith </td><td>44552</td><td>New England Journal of Medicine</td><td>Comment</td><td>Additional Analysis Required</td><td>Inquiries are made regarding the length of protection provided by the booster and the schedule of delivery.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2115624#article_comments</td></tr>
<tr><td>19</td><td>Status of the third doses vaccination of COVID-19 mRNA Vaccine in Japan</td><td>Takuma Hayashi</td><td>44552</td><td>New England Journal of Medicine</td><td>Comment</td><td>Additional Analysis Required</td><td>Considering that the frequency of adverse events after the second dose is higher in Japan compared to other countries, there are concerns pertaining to the rollout of the third dose of the vaccine.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2115624#article_comments</td></tr>
<tr><td>19</td><td>Where are the overall mortality data?</td><td>Reimar Fritzen</td><td>44553</td><td>New England Journal of Medicine</td><td>Comment</td><td>Additional Analysis Required</td><td>Additional analysis is requested for booster effectiveness when considering all cause mortality.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2115624#article_comments</td></tr>
<tr><td>19</td><td>Effectiveness of a third dose of the BNT162b2 Vaccine</td><td>Prem raj Pushpakaran </td><td>44556</td><td>New England Journal of Medicine</td><td>Comment</td><td>Additional Data</td><td>Additional longer-term data for the safety of boosters is required to have a better understanding on their effectiveness, especially for immuno-compromised individuals or those with underlying illnesses.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2115624#article_comments</td></tr>
<tr><td>19</td><td>and after ?</td><td>Marta Salvi </td><td>44558</td><td>New England Journal of Medicine</td><td>Comment</td><td>Additional Analysis Required</td><td>An inquiry is made pertaining to longer-term health outcomes after receiving the booster.</td><td>https://www.nejm.org/doi/full/10.1056/NEJMoa2115624#article_comments</td></tr>
  	</tbody>

    <script type="text/javascript">
	$('#bs-table').DataTable(); 
    </script>

  </body>
</html>
